MUSC/HCC Paul Calabresi Clinical Oncology Training Program Plan

MUSC/HCC Paul Calabresi 临床肿瘤学培训计划计划

• 批准号: 9242567
• 负责人: MICHAEL B LILLY
• 金额: $ 53.71万
• 依托单位: MEDICAL UNIVERSITY OF SOUTH CAROLINA
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-04-01 至 2018-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9242567
• 关键词: Adult; Antineoplastic Agents; Applications Grants; Appointment; Area; Award; Basic Science; Biological; Cancer Center; Charge; Childhood; Clinic; Clinical; Clinical Oncology; Clinical Research; Clinical Sciences; Communities; Dental; Discipline of Nursing; Doctor of Pharmacy; Doctor of Philosophy; Ensure; Faculty; Funding; Funding Agency; Goals; Gynecologic Oncology; Laboratories; Laboratory Research; Malignant Neoplasms; Master of Science; Medical; Medicine; Mentored Clinical Scientist Development Program; Mentors; Monitor; National Cancer Institute; Neurologic; Nurses; Operative Surgical Procedures; Otolaryngology; Participant; Pharmacy facility; Population Sciences; Postdoctoral Fellow; Prevention; Provider; Publishing; Qualifying; Radiation; Recruitment Activity; Reporting; Research; Research Personnel; Resources; Rotation; SECTM1 gene; Schedule; Science; Scientist; Senior Scientist; Services; South Carolina; Therapy trial; Time; Training; Training Programs; Translational Research; Translations; United States National Institutes of Health; Universities; Urology; Work; base; cancer care; cancer immunotherapy; cancer therapy; career development; clinical application; cohort; college; design; drug development; experience; insight; knowledge base; medical specialties; mortality disparity; next generation; oncology; patient oriented; patient oriented research; programs

DESCRIPTION (provided by applicant): The Medical University of South Carolina's Hollings Cancer Center (MUSC/HCC) is committed to providing a physical and intellectual space to nurture tomorrow's leaders in clinical and translational oncology research. To accomplish this end, MUSC/HCC will establish the Paul Calabresi Clinical & Translational Oncology Training Program focused in three areas - cancer drug development, cancer immunotherapy, and cancer population sciences. The goal of this Program is to train successful, patient-oriented, clinical- and laboratory-based investigators who can work effectively in a collaborative, translational research setting. At the completion of the Program, these researchers will be able to independently design, implement and manage patient-oriented studies emphasizing both the translation of laboratory research findings into clinical applications, as well as laboratory studis examining the basic mechanisms of poorly understood clinical phenomena. Chosen participants, called Calabresi Scholars, will already hold a clinical or basic science qualifying professional degree. Clinically oriented Scholars will have recently completed postgraduate training in medical (adult or pediatric), radiation, surgical (including urology, otolaryngology, ad neurological subspecialties), or gynecologic oncology and will be ready for a first faculty appointment. Basic science Scholars will have a PhD or PharmD, will have completed at least two years of post-doctoral experience, and will be ready to develop a clinically-oriented, but laboratory-based, research program. To ensure the maturation of their knowledge base in clinical and translational research, each MUSC/HCC Calabresi Scholar will use the support from this K12 to develop a training plan within one of the three tracks in conjunction with an experienced mentoring team comprised of senior scientists (MDs and PhDs). Training will entail intensive course work (potentially leading to a Master of Science in Clinical Research) and an opportunity to participate in multiple, short-term laboratory and clinical research rotations durin the first quarter of the first year of training. This will be followed by a continuous, mentored, longitudinal laboratory and clinical research experience during the remainder of the first and second years of training. Each Scholar will be expected to complete three different but related milestones. Each Scholar will design and initiate a clinical cancer therapy trial (MD/DO Scholars) or a correlative science study (PhD/PharmD scholars), to answer a biological hypothesis-based clinical research question. As a second milestone, at least two publishable research reports should emanate from each of the Scholar's studies. Finally, the Scholar will be expected to create a fully developed grant application and submit it to a funding agency. An interdisciplinary Advisory Council will work closely with the Program Co-Directors in Year 01 to finalize all of the details of each training component and to have adequate time to recruit, externally and internally, for the best cohort of Scholars. Beginning in Year 02, the Program will appoint one or two Scholars annually, for a total of six Scholars. This MUSC/HCC Calabresi Training Program has been designed for a two year commitment. The Scholars will be selected by the Advisory Council, and the Advisory Council will also be charged to carefully monitor and evaluate each Scholar and the overall Program on a frequent and regular schedule. All Program components will utilize the considerable experience of scientists and mentors originating from MUSC's Colleges of Medicine, Pharmacy, Dental Medicine, Nursing and Graduate Medical Sciences, as well as the considerable research resources provided by the Hollings Cancer Center, a National Cancer Institute designated cancer center. The Program will also take full advantage of the career development services as part of MUSC's NIH funded Clinical and Translational Science Award. This K12 Program will provide the opportunity to maximize the HCC's potential in patient-oriented research while ensuring that the next generation of scientists is prepared to expedite the translation of science into the clinic and community. Another hallmark feature of this proposed K12 Program is that it is based in South Carolina, a state characterized by high cancer mortality, disparities and limited specialty providers, thus affording the Scholars with exceptional insight into the potential challenges of disseminating new standards of cancer care, prevention, and control emanating from the latest research.

描述(由申请人提供)：南卡罗来纳医科大学霍林斯癌症中心(MUSC/HCC)致力于提供一个物理和智力空间，以培养未来临床和转化性肿瘤学研究的领导者。为了实现这一目标，MUSC/HCC将建立Paul Calabresi临床和转化性肿瘤学培训计划，重点放在三个领域--癌症药物开发、癌症免疫治疗和癌症人口科学。该计划的目标是培养成功的、以患者为中心、以临床和实验室为基础的研究人员，他们能够在合作的、转化性的研究环境中有效地工作。在该计划完成后，这些研究人员将能够独立设计、实施和管理以患者为中心的研究，强调将实验室研究成果转化为临床应用，以及研究鲜为人知的临床现象的基本机制的实验室研究。被选中的参与者被称为卡拉布雷西学者，他们将已经拥有临床或基础科学资格的专业学位。面向临床的学者最近将完成内科(成人或儿科)、放射、外科(包括泌尿外科、耳鼻喉科、神经科)或妇科肿瘤学的研究生培训，并将为首次教职做好准备。基础科学学者将拥有博士或药学博士学位，至少完成两年的博士后工作经验，并准备开发以临床为导向，但以实验室为基础的研究计划。为了确保他们在临床和转化性研究方面的知识库的成熟，每一位MUSC/HCC Calabresi学者将利用本K12的支持，与由资深科学家(医学博士和博士)组成的经验丰富的指导团队一起，在三个轨道之一制定培训计划。培训将需要密集的课程工作(可能会获得临床研究理学硕士学位)，并有机会在第一年第一季度参加多次短期实验室和临床研究轮换。之后，在第一年和第二年培训的剩余时间里，将有持续的、有指导的、纵向的实验室和临床研究经验。每位奖学金获得者将被期望完成三个不同但相关的里程碑。每位学者将设计并发起一项临床癌症治疗试验(MD/DO学者)或相关科学研究(博士/药学学者)，以回答基于生物学假说的临床研究问题。作为第二个里程碑，这位学者的每一项研究都应该至少发表两份可发表的研究报告。最后，预计奖学金获得者将创建一份全面开发的拨款申请，并将其提交给资助机构。一个跨学科咨询委员会将在01年与计划联合主任密切合作，最终确定每个培训部分的所有细节，并有足够的时间从外部和内部招募最佳学者。从02年开始，该计划将每年任命一到两名学者，总共六名学者。该MUSC/CC Calabresi培训计划的设计期限为两年。奖学金获得者将由顾问委员会选出，顾问委员会还将负责定期、频繁地对每一名奖学金获得者和整个计划进行仔细的监测和评估。所有计划组成部分都将利用来自南加州大学医学院、药剂学、牙科医学院、护理学院和研究生医学学院的科学家和导师的丰富经验，以及霍林斯癌症中心提供的大量研究资源。霍林斯癌症中心是美国国家癌症研究所指定的癌症中心。该计划还将充分利用职业发展服务，作为南加州大学国立卫生研究院资助的临床和翻译科学奖的一部分。这一K12计划将提供机会，最大限度地发挥肝细胞癌以患者为中心的研究潜力，同时确保下一代科学家做好准备，加快将科学转化为临床和社区。这项拟议的K12计划的另一个特点是，它的总部设在南卡罗来纳州，该州的特点是癌症死亡率高，差异大，专业提供者有限，因此能够提供 学者们对传播最新研究产生的癌症护理、预防和控制的新标准的潜在挑战具有特殊的洞察力。